Breast cancer characteristics at diagnosis and survival among Arab-American women compared to European- and African-American women

Breast Cancer Res Treat. 2009 Mar;114(2):339-46. doi: 10.1007/s10549-008-9999-z. Epub 2008 Apr 15.

Abstract

Background: Data from Arab world studies suggest that Arab women may experience a more aggressive breast cancer phenotype. To investigate this finding, we focused on one of the largest settlements of Arabs and Iraqi Christians (Chaldeans) in the US, metropolitan Detroit- a SEER reporting site since 1973.

Materials and methods: We identified a cohort of primary breast cancer cases diagnosed 1973-2003. Using a validated name algorithm, women were identified as being of Arab/Chaldean descent if they had an Arab last or maiden name. We compared characteristics at diagnosis (age, grade, histology, SEER stage, and marker status) and overall survival between Arab-, European-, and African-Americans.

Results: The cohort included 1,652 (2%) women of Arab descent, 13,855 (18%) African-American women, and 63,615 (80%) European-American women. There were statistically significant differences between the racial groups for all characteristics at diagnosis. Survival analyses overall and for each SEER stage showed that Arab-American women had the best survival, followed by European-American women. African-American women had the poorest overall survival and were 1.37 (95% confidence interval: 1.23-1.52) times more likely to be diagnosed with an aggressive tumor (adjusting for age, grade, marker status, and year of diagnosis).

Conclusion: Overall, Arab-American women have a distribution of breast cancer histology similar to European-American women. In contrast, the stage, age, and hormone receptor status at diagnosis among Arab-Americans was more similar to African-American women. However, Arab-American women have a better overall survival than even European-American women.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Arabs*
  • Biomarkers, Tumor / metabolism
  • Black or African American*
  • Breast Neoplasms / diagnosis*
  • Breast Neoplasms / epidemiology
  • Breast Neoplasms / mortality*
  • Carcinoma in Situ / diagnosis
  • Carcinoma in Situ / epidemiology
  • Carcinoma in Situ / mortality
  • Carcinoma, Ductal, Breast / diagnosis
  • Carcinoma, Ductal, Breast / epidemiology
  • Carcinoma, Ductal, Breast / mortality
  • Carcinoma, Lobular / diagnosis
  • Carcinoma, Lobular / epidemiology
  • Carcinoma, Lobular / mortality
  • Carcinoma, Medullary / diagnosis
  • Carcinoma, Medullary / epidemiology
  • Carcinoma, Medullary / mortality
  • Cohort Studies
  • Female
  • Humans
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Risk Factors
  • SEER Program
  • Survival Rate
  • White People*

Substances

  • Biomarkers, Tumor